Hannes Hagström
458 works · 19,843 citations · h-index 60
Top works
- Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
- Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
- Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
- Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis
- Advancing the global public health agenda for NAFLD: a consensus statement
- Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
- Changing epidemiology, global trends and implications for outcomes of NAFLD
- Adaptation of the Charlson Comorbidity Index for Register-Based Research in Sweden
- 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical
- Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long‐term follow‐up study
- Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study
- Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease
- Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement
- Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort
- Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease
- Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease
- FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
- Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events
- Natural history and progression of metabolic dysfunction-associated steatotic liver disease